Yuehui Wu

发表

Adaptive designs for selecting drug combinations based on efficacy–toxicity response

Valerii V. Fedorov, Vladimir Dragalin, Yuehui Wu, 2008 .

Two‐stage design for dose‐finding that accounts for both efficacy and safety

Vladimir Dragalin, Yuehui Wu, V. Fedorov, 2008, Statistics in medicine.

Dose Finding Designs for Continuous Responses and Binary Utility

Yuehui Wu, V. Fedorov, Yuehui Wu, 2007, Journal of biopharmaceutical statistics.

Letter regarding article ‘Abdominal aortic aneurysm is associated with subarachnoid hemorrhage’

Yuehui Wu, Xiaobing Jiang, Xinyu Yu, 2021, Journal of NeuroInterventional Surgery.

Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.

Keunchil Park, D. Gandara, J. Infante, 2013 .

Phase I/II Trial of the MEK1/2 Inhibitor Trametinib (GSK1120212) in Relapsed/Refractory Myeloid Malignancies: Evidence of Activity in Patients with RAS Mutation-Positive Disease

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2012 .

Treatment Response in Patients with Primary Colonic Lymphomas: Experience in a Single Institute

Yuehui Wu, Chia-Lo Chang, Hong-Hwa Chen, 2012 .

Abstract CT014: GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I/II open-label single-agent study in patients with NUT midline carcinoma (NMC) and other cancers

G. Shapiro, R. Prinjha, S. Piha-Paul, 2016 .

Letter to the Editor Regarding "Association Between Aspirin Use and Risk of Aneurysmal Subarachnoid Hemorrhage: A Meta-Analysis".

Yuehui Wu, Xiaobing Jiang, Xinyu Yu, 2021, World neurosurgery.

Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).

R. Bernards, C. Atreya, J. Schellens, 2014 .

Non-Coding RNAs as Circulating Biomarkers for the Diagnosis of Intracranial Aneurysm: A Systematic Review and Meta-Analysis.

Hongyang Zhao, Yuehui Wu, Xiaobing Jiang, 2021, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

Optimal dose‐finding designs with correlated continuous and discrete responses

Valerii Fedorov, Yuehui Wu, V. Fedorov, 2012, Statistics in medicine.

Dose Finding Experiments: Responses of Mixed Type

Valerii V. Fedorov, Rongmei Zhang, Yuehui Wu, 2010 .

Generalized Probit Model in Design of Dose Finding Experiments

V. Fedorov, Yuehui Wu, 2007 .

Optimal Design for Dose Response Using Beta Distributed Responses

V. Fedorov, K. Propert, Yuehui Wu, 2005, Journal of biopharmaceutical statistics.

Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory Small Cell Lung Cancer.

R. Govindan, R. Kruger, B. Besse, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Phase I Study of GSK525762, a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of Phase I/II Open Label Single Agent Study in Patients with Acute Myeloid Leukemia (AML)

M. Dawson, M. Tallman, G. Borthakur, 2017 .

Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I/II open‐label, dose escalation study

J. Blay, R. Plummer, G. Shapiro, 2021, International journal of cancer.

Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors

G. Shapiro, R. Prinjha, I. Braña, 2019, JNCI cancer spectrum.

A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non–Small Cell Lung Cancer

K. Kelly, D. Gandara, F. Shepherd, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Activity of the oral mitogen‐activated protein kinase kinase inhibitor trametinib in RAS‐mutant relapsed or refractory myeloid malignancies

H. Kantarjian, G. Garcia-Manero, T. Kadia, 2016, Cancer.

The Role of Aspirin in the Management of Intracranial Aneurysms: A Systematic Review and Meta-Analyses

Yuehui Wu, Liangtao Xia, Xinyu Yu, 2021, Frontiers in Neurology.

Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC).

C. Atreya, J. Schellens, J. Tabernero, 2015 .

Letter by Wu and Yu Regarding Article, "Smoking Causes Fatal Subarachnoid Hemorrhage: A Case-Control Study of Finnish Twins".

Yuehui Wu, Xinyu Yu, 2021, Stroke.